Načítá se...
Direct oral anticoagulant use and risk of severe COVID‐19
BACKGROUND: Hypercoagulability and thromboembolism are prominent features of severe COVID‐19, and ongoing anticoagulant use might be protective. METHODS: We conducted a nationwide register‐based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (...
Uloženo v:
| Vydáno v: | J Intern Med |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753564/ https://ncbi.nlm.nih.gov/pubmed/33258156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13205 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|